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ttp://dx.doi.org/10.1016/j.jmoldx.2017.05.004Recurrent and clonal genetic alterations are characteristic of different subtypes of T- and B-cell
lymphoblastic leukemia (ALL), and several subtypes are strong independent predictors of clinical
outcome. A next-generation sequencingebased multiplex ligation-dependent probe ampliﬁcation
variant (digitalMLPA) has been developed enabling simultaneous detection of copy number al-
terations (CNAs) of up to 1000 target sequences. This novel digitalMLPA assay was designed and
optimized to detect CNAs of 56 key target genes and regions in ALL. A set of digital karyotyping
probes has been included for the detection of gross ploidy changes, to determine the extent of
CNAs, while also serving as reference probes for data normalization. Sixty-seven ALL patient
samples (including B- and T-cell ALL), previously characterized for genetic aberrations by stan-
dard MLPA, array comparative genomic hybridization, and/or single-nucleotide polymorphism
array, were analyzed single blinded using digitalMLPA. The digitalMLPA assay reliably identiﬁed
whole chromosome losses and gains (including high hyperdiploidy), whole gene deletions or
gains, intrachromosomal ampliﬁcation of chromosome 21, fusion genes, and intragenic deletions,
which were conﬁrmed by other methods. Furthermore, subclonal alterations were reliably detected
if present in at least 20% to 30% of neoplastic cells. The diagnostic sensitivity of the digi-
talMLPA assay was 98.9%, and the speciﬁcity was 97.8%. These results merit further consider-
ation of digitalMLPA as a valuable alternative for genetic work-up of newly diagnosed ALL
patients. (J Mol Diagn 2017, 19: 659e672; http://dx.doi.org/10.1016/j.jmoldx.2017.05.004)Supported in part by the Kinderkankerfonds vzw (T.L.), the Research
Foundation Flanders (Odysseus; P.V.V.), and Bloodwise (formerly Leu-
kemia and Lymphoma Research, UK; C.S. and C.J.H.).
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Holland, the company developing the commercially available multiplex
ligation-dependent probe ampliﬁcation products used in this study. J.S. is a
100% shareholder of MRC-Holland.T- and B-cell lymphoblastic leukemia (T- and B-ALL,
respectively) is the most common childhood cancer and
shows profound heterogeneity at the clinical and genetic
level. Classiﬁcation of ALL is based on immunophenotype,
taking into account the lymphocyte lineage (B cell, T cell, or
mixed lineage). However, within these groups, genetic
subtypes exist, with great differences in clinical outcomestigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc.
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0).
Benard-Slagter et aland treatment response.1e4 Genetic changes in ALL include
copy number alterations (CNAs) of genes involved in
lymphocyte lineage differentiation and cell cycle control,
gene rearrangements, fusion genes, and whole chromosomal
losses or gains. A combination of technologies, such as
ﬂuorescence in situ hybridization (FISH), immunopheno-
typing, array comparative genomic hybridization (aCGH),
and single-nucleotide polymorphism (SNP) arrays has made
it possible to detect these key genetic abnormalities and
thereby distinguish the different subtypes of ALL. However,
these techniques and associated data analysis are costly and
labor intensive.
Multiplex ligation-dependent probe ampliﬁcation
(MLPA)5 has become one of the standard methods for the
detection of common CNAs, such as IKZF1 deletions
associated with poor outcome in B-ALL.6 MLPA has been
shown to perform with high concordance to FISH, chro-
mogenic in situ hybridization, and quantitative PCR.6,7
However, standard MLPA assays are restricted to a
maximum of 60 MLPA probes and require a minimum of
50 ng of good quality DNA. As some of the genetic
subtypes in ALL are complex, and may encompass mul-
tiple chromosomal locations, there is need for an improved
approach to simultaneously perform copy number analysis
of multiple regions with high sensitivity and speciﬁcity. To
address this need, a next-generation sequencingebased
MLPA variant (digitalMLPA) has been developed with the
potential to include up to 1000 probes in a single reaction.
In addition, minimal amounts of DNA are required (20
ng) for robust performance of the assay. In the digital-
MLPA assay described herein, 642 probes were included,
targeting the following: i) all genes/regions included in
ﬁve standard MLPA assays (MRC-Holland, Amsterdam,
the Netherlands) used routinely on diagnostic ALL patient
samples: P202 IKZF1 (IKAROS), P327 iAMP21-ERG,
P329 CRLF2-CSF2RA-IL3RA, P335 ALL-IKZF1, and
P383 T-ALL; ii) additional target genes of potential
prognostic and/or therapeutic relevance in ALL, including
NOTCH1, CD200/BTLA, VPREB1, TBL1XR1, EBF1-
PDGFRB, IGHM, NR3C1/2, CREBBP, CTCF, ADD3,
EPHA1, FHIT, SPRED1, DMD, and TOX; and iii) a set of
208 digital karyotyping probes for detection of ploidy
changes (hyperdiploidy or hypodiploidy), to determine the
extent of copy number changes, and to be used as refer-
ence probes for data normalization.
After extensive validation of the novel digitalMLPA
probes on normal samples and positive cell lines
harboring known CNAs, a validation study was per-
formed on 67 ALL patient samples previously character-
ized using other methods (aCGH and/or SNP arrays and
standard MLPA assays). Samples were analyzed single
blinded (A.B. and S.S.). The sensitivity and speciﬁcity of
the assay were calculated by comparing the digitalMLPA
data to the data previously obtained by other methods.
Finally, the detection limits for subclonal CNAs were
determined.660Materials and Methods
Development of DigitalMLPA Probe Mix for ALL
The digitalMLPA D007 ALL probe mix was designed to
contain probes for genes and chromosomal regions known or
proposed to have signiﬁcant diagnostic or prognostic roles in
ALL, selected by extensive literature review and suggestions
from experts in the ﬁeld of ALL research. In the literature
review, we focused on recurrent reports of CNAs in indi-
vidual genes and possible clinical relevance in terms of
prognostic and/or diagnostic use for ALL, when available.
Both B-ALLe and T-ALLeassociated CNAs were included
in this digitalMLPA D007 ALL probe mix (X2-0816) up to a
total of 306 target-speciﬁc probes for 56 target genes (at least
three probes per gene when possible), 27 different genes on
chromosome 21 (including RUNX1) to detect intra-
chromosomal ampliﬁcation of chromosome 21 (iAMP21),
and ﬂanking probes for the pseudoautosomal region 1
(Figure 18 and Supplemental Table S1). The set of 208 digital
karyotyping probes covers all chromosome armswith three to
six probes, with at least one probe on each of the following
locations: close to the centromere, middle of the chromosome
arm, and close to the telomere (Supplemental Table S2).Most
target probes were designed to locate in the coding sequence
of the target genes. Inclusion of probes for speciﬁc exons
within each target gene was based on breakpoint information
and those exons most frequently affected by intragenic de-
letions. A set of 128 internal quality control probes was also
included to determine reaction quality, to determine amount
of input DNA, and for troubleshooting purposes. These
include a set of 39 pairs of SNP probes for sample identiﬁ-
cation and detection of sample contamination.Probe Design for the DigitalMLPA D007 ALL Assay
Probes were designed based on University of California,
Santa Cruz, Human Genome build GRCh37/hg19. Probes
consist of two parts, the right- and left-hybridizing sequences,
which are ligated only when bound adjacent to each other on
their target DNA. Ligation sites of most probes are located
within exons, as existing sequence information of exons is
more reliable than it is for intronic sequences. SNPs at and
around the ligation site can affect the probe ligation and were,
therefore, checked using the dbSNP146 database to avoid
frequent and validated SNPs. SNPs can also reduce a probe
signal by destabilizing probe-sample DNA binding. The
length and melting temperature of each probe oligonucleotide
were therefore chosen in such a way as to ensure stable
binding to the target DNA even in the presence of known
SNPs. As each submission of sequence data provides more
information about possible SNPs in the human genome, there
is always a possibility of an SNP being present at the ligation
site, which might inﬂuence probe binding and ligation and
might thereby cause a false-negative result. Multiple probes
were included for each target gene/region to preventjmd.amjpathol.org - The Journal of Molecular Diagnostics
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Figure 1 Target genes included in the D007 ALL digitalMLPA probe mix. Circos plot visualizing all target genes included in the D007-X2-0816 ALL
digitalMLPA probe mix. The Circos plot was made using the Progenetix database (arraymap data)8 at http://www.progenetix.org, using subset “Leukemias:
immature acute lymphoblastic leukemias,” which at the moment of generation of the ﬁgure consisted of 1067 samples from 40 publications. Numbers in
parentheses refer to the number of probes included for the respective gene. In blue are the target genes with an expected copy number gain, in red the
target genes with an expected copy number loss. Chromosome bands are indicated for each of the genes/regions. In the middle line of the Circos plot,
the expected percentages of CNAs in immature ALL, according to the Progenetix database, are indicated (gains in blue and losses in red).
DigitalMLPA for T- and B-ALLconclusions being based on single-probe alterations. Single-
probe alterations should always be conﬁrmed by a different
method.
DigitalMLPA Experiments
DigitalMLPA was developed on the basis of the
well-established MLPA method,5 but uses Illumina next-
generation sequencing platforms for amplicon quantiﬁca-
tion (Figure 2). Brieﬂy, 40 ng (in a total volume of 4 mL) of
each DNA sample was mixed with 2 mL of a unique
barcode solution (MRC-Holland), followed by DNA
denaturation at 98C for 10 minutes. After denaturation, a
mixture of 1.25 mL digitalMLPA probe mix (MRC-
Holland) and 1.25 mL digitalMLPA buffer (MRC-Holland)The Journal of Molecular Diagnostics - jmd.amjpathol.orgwas added to each sample, and reactions were incubated
overnight at 60C to ensure hybridization of the probes to
the target DNA. Probes were ligated by incubating the
reactions with 32 mL of a ligase mastermix containing
the ligase-65 enzyme (MRC-Holland) and buffers (MRC-
Holland) at 48C for 30 minutes, followed by heat inacti-
vation of the ligase-65 enzyme at 98C for 5 minutes and
an additional incubation at 65C for 20 minutes to reduce
background. PCR ampliﬁcation of the ligated probes was
performed on a calibrated Biometra thermocycler (Bio-
metra GmbH, Göttingen, Germany). The PCR-ampliﬁed
products were then loaded onto an Illumina MiSeq
sequencer (Illumina, San Diego, CA) for quantiﬁcation
using the MiSeq Reagent Kit version 3 (150 cycles;
Illumina).661
Figure 2 DigitalMLPA procedure. In digitalMLPA, sequencing is used solely to determine absolute read numbers of the various probe amplicons, not for
sequence analysis of the sample DNA. As with conventional MLPA, reference DNA samples, preferably treated and extracted the same way as the DNA samples
to be tested, are required to determine the relative copy number of each of the probes. A: After denaturation of the target DNA, the left (LPO) and right probe
oligo (RPO) are hybridized to their target sequence overnight (at least 16 hours). B: The next day, the two oligonucleotides are enzymatically ligated and a
barcode oligo (BO) is incorporated into the amplicon for sample identiﬁcation. The Rd1 sequence, as part of the BO, is the Illumina tag required for
quantiﬁcation by Illumina sequencers (Illumina, San Diego, CA). C and D: After PCR (C), amplicons are quantiﬁed using Illumina sequencers (D). E: Absolute
read counts are compared with reference samples to obtain probe ratios.
Benard-Slagter et alQuality Tests and Validation on Positive Cell Line
Samples
All probes included in the digitalMLPA ALL probe mix were
extensively quality tested for stability and variability on DNA
from healthy individuals, according to internal guidelines and
protocols of MRC-Holland. General probe performance was
tested on Promega Human Genomic male DNA (Promega
Benelux, Leiden, the Netherlands). Variability of the probes
was tested on DNA of 48 healthy individuals; probes with an662SD of >0.08 were excluded from the probe mix and/or
replaced with a newly designed probe. Sensitivity of probes
to various experimental conditions, mimicking possible
pipetting mistakes, deviating thermocycler temperatures, and
giving variation in sample DNA quantity and quality, was
also tested. Nonspeciﬁc probe oligo interactions were
screened in reactions without DNA added (Tris-EDTA
alone), and probes causing formation of nonspeciﬁc products
likely to consume reads from the correctly ligated probes
were removed or replaced. Lastly, the digitalMLPA ALLjmd.amjpathol.org - The Journal of Molecular Diagnostics
DigitalMLPA for T- and B-ALLprobe mix was tested on commercial cell lines (Coriell Bio-
repositories, Camden, NJ; and European Collection of
Authenticated Cell Cultures, Salisbury, UK) and research
samples obtained from collaborating universities (Erasmus
University Rotterdam, Rotterdam, the Netherlands; Leiden
University, Leiden, the Netherlands; Utrecht University,
Utrecht, the Netherlands; and University of Bonn, Bonn,
Germany) harboring different well-characterized CNAs,
including intragenic deletions, whole-gene deletions, and
whole chromosome gains and losses.
Validation of the DigitalMLPA ALL Assay on ALL Patient
Samples
DNA samples from patients with conﬁrmed ALL were ob-
tained from three different research laboratories (Ghent
University, Ghent, Belgium; University of Helsinki, Helsinki,
Finland; and Newcastle University, Newcastle upon Tyne,
UK) and tested single blinded (A.B. and S.S.) at MRC-
Holland. DNA was obtained from bone marrow or peripheral
blood primary samples and extracted using the DNeasy
Blood and Tissue Kit (Qiagen Benelux, Venlo, the
Netherlands). The percentage of ALL blast cells in each
sample was estimated to be at least 70%. digitalMLPA ex-
periments were performed using 40 ng of sample DNA.
Reference samples included in each experiment were tripli-
cates of Promega male DNA. A total of 67 ALL patient
samples were analyzed in this study: 9 T-ALL and 27 B-ALL
samples from Ghent University, 1 T-ALL and 10 B-ALL
samples from the University of Helsinki, and 20 B-ALL
samples from Newcastle University. Concordance of digi-
talMLPA data with previously performed aCGH (Ghent
University: Agilent180K custom-designed oligonucleotide
array platform9; University of Helsinki: Agilent 244k CGH
microarrays10,11) and/or SNP arrays [University of Helsinki:
Affymetrix Genome-Wide Human 6.0 SNP arrays10,11;
Newcastle University: SNP 6.0 (Affymetrix, Santa Clara,
CA)], performed by AROS Applied Biotechnology (Aarhus,
Denmark),12,13 was checked independently by each of the
research institutes. Samples from Ghent University and the
University of Helsinki were analyzed using the D007-X1-
0316 ALL digitalMLPA probe mix. After analyzing the re-
sults of these patient samples, the product was updated to
include several additional target genes having potential
prognostic value in ALL (FHIT, EPHA1, TOX, MTAP,
ADD3, SPRED1, CREBBP, CTCF, and DMD), and probes
showing high variability (SD, >0.10) or formation of
nonspeciﬁc ampliﬁcation products were removed. Samples
from Newcastle University were analyzed with the updated
D007-X2-0816 ALL digitalMLPA probe mix.
Validation of the DigitalMLPA ALL Assay Using
Standard MLPA Assays
To compare the results of this new digitalMLPA assay with
those of the well-known and extensively tested standardThe Journal of Molecular Diagnostics - jmd.amjpathol.orgMLPA assays, patient samples from Ghent University were
tested with MLPA assay P335-B2-0614 ALL-IKZF1, which
includes probes for the pseudoautosomal region 1, EBF1,
IKZF1, CDKN2A/B, PAX5, ETV6, BTG1, and RB1. Samples
from the University of Helsinki were tested with P335-A4-
0111, and samples from Newcastle University were tested
with P335-A3 (N01, N02, N04-N06, N08, N09, and N12-
N18), P335-A4 (N03 and N20), or P335-B1 (N07). Sam-
ples N10, N11, and N19 were not tested with the P335
standard MLPA assay. In addition, several samples with
suspected iAMP21 (N04-N08 and N10-N13) were tested
with MLPA assay P327-B1 iAMP21-ERG containing
probes for the region 21q11.2-21q22.3, including RUNX1
and ERG. All probes included in these two standard MLPA
probe mixes have equivalents in the digitalMLPA D007
ALL assay, but with different ligation sites, and could
therefore be used for independent validation and veriﬁcation
of the ﬁndings observed with the digitalMLPA assay.Dilution Series to Determine Detection Limits of
Subclonal CNAs
A dilution series of three B-ALL patient samples (Ghent
University) was analyzed to determine the detection limit
for subclonal CNAs. The patient samples were diluted with
corresponding remission material, to mimic the following
percentages of subclonal populations: 50%, 30%, 25%,
20%, 15%, and 10%. Experiments using the digitalMLPA
D007 ALL probe mix (X2-0816) were performed single
blinded (A.B. and S.S.) at MRC-Holland using 40 ng of
sample DNA. The read ratios of the undiluted patient
samples (100%) were used as a reference to match the read
counts in the diluted samples to a patient sample and a
dilution percentage. Correct matching of the dilution per-
centages and patient samples was conﬁrmed by Ghent
University. The detection limit for subclonal CNAs was
determined as follows: we used a value of 0.12, two times
the average SD in DNA from healthy individuals across all
probes included in the probe mix, to determine the limits of
normal copy number. In other words, any read ratio outside
of 0.88 to 1.12 was regarded as a potential deletion/gain,
respectively. When two consecutive probes had ratios
outside of this range, this was regarded as a true CNA call in
this dilution series.Dilution Series with Low Amounts of Input DNA for the
DigitalMLPA Assay
To demonstrate that this digitalMLPA assay also produces
robust results when the amount of input DNA is low, we
performed experiments on serial dilutions of input DNA.
The following amounts of input DNA per experiment were
tested: 40 (standard), 30, 20, 15, 10, and 5 ng. Triplicates of
40 ng of Promega male DNA were used as a reference. The
experiments were performed on three research samples from663
Benard-Slagter et althe collection of MRC-Holland, of which one is a cell line
(sample 1) and two are B-ALL patient samples.
Data Analysis of DigitalMLPA
For analysis of MiSeq data, FASTQ ﬁles were exported. To
analyze the FASTQ ﬁles, software was designed at MRC-
Holland that assigned each read in the FASTQ ﬁle to a
complete digitalMLPA probe. Each read consisted of mul-
tiple parts: barcode, constant region, right-hybridizing
sequence, and left-hybridizing sequence. Each part was
analyzed using the Levenshtein distance algorithm14 that
determines the number of insertions, deletions, and sub-
stitutions needed to change one sequence into another
sequence. The ﬁrst 10 nucleotides of the read contain the
barcode sequence and were used to assign the read to a
DNA sample. The second part of the read is a constant
sequence of 26 nucleotides that was used to determine
whether the read was a digitalMLPA product. All other,
non-MLPA reads obtained from other experiments com-
bined in the same (MiSeq) run, were ignored. After this
constant region, the right-hybridizing sequence of the probe
was used to ﬁnd the corresponding probe. Using the Lev-
enshtein distance algorithm, the last part of the read was
then used to verify that the correct left-hybridizing
sequence, and hence the correct combination of two
ligated probe oligonucleotides, was present in the read. This
allowed for detection/ﬁltering of reads that are due to
unanticipated interactions between any of the oligonucleo-
tides present in each reaction. If the read could not be
assigned to a speciﬁc probe included in the probe mix, the
read was classiﬁed as unidentiﬁed. For further data analysis,
read ratios of the probes are determined as in standard
MLPA experiments, but using read counts instead of peak
height. Read counts per probe were ﬁrst compared with the
median value of all reference probes in each sample. In a
second step, the normalized values of each individual probe
were compared with the median value of the corresponding
probe in the reference samples; these were the ﬁnal read
ratios. A read ratio of 1.0 indicated normal copy number
(n Z 2) for autosomal gene regions, a read ratio of 0.5
indicated a heterozygous deletion, and a read ratio of 1.5
indicated a gain of one copy of the target sequence in a
sample with 100% tumor cell percentage consisting of only
one major clone. For X and Y chromosomal regions (except
for genes located in the pseudoautosomal region 1 present
on both X and Y chromosomes and, therefore, behaving as
autosomal gene regions), a copy number of one was used as
the normal copy number as the reference DNA used was
male. When analyzing X and Y chromosomal regions, the
sex of the patient was taken into account when interpreting
the results. In females, the read ratio of X chromosome
probes was divided by 2. A read ratio of 1.0 of an X-
chromosomal region in a female would indicate a hetero-
zygous deletion, whereas in males this indicates a normal
copy number.664Results
Quality Testing on Healthy DNA Samples and
Validation on Positive Cell Lines
In all digitalMLPA experiments, MiSeq runs generated
approximately 600 single reads of at least 100 nucleotides in
length for each probe in the reference DNA samples. Ten of
a total of 642 probes were replaced on the basis of low read
count, variation in normal healthy DNA samples, or for-
mation of nonspeciﬁc ampliﬁcation products. All probes
included in this digitalMLPA probe mix showed minimal
variability (SD, <0.08), had a relative read ratio of 0.80 to
1.20 as compared with the average read number across all
autosomal probes, and did not form any harmful nonspeciﬁc
ampliﬁcation products. The mean SD across all target and
reference probes on 48 healthy samples derived from blood
was 0.06. Validation of the digitalMLPA ALL assay on
positive cell lines harboring well-identiﬁed copy number
changes showed accurate detection of all previously re-
ported whole gene deletions (TP53, RB1, CDKN2A,
CDKN2B, NOTCH1, and PTEN ) or gains (CRLF2), gain of
whole chromosomes (trisomies 13, 15, 18, 21, 22, and X),
gain (3q) or deletion (18p, 3p telomere, 14q, and 18q) of
chromosome arms, and intragenic deletions (TP53 exons 10
to 11, NF1 exon 26, and PTEN exons 1 to 2) in these cell
lines (Supplemental Table S3).Validation on ALL Patient Samples
Two samples were excluded from the analyses because of
poor sample quality (H07 and G23; also failed on aCGH), as
evidenced by high variability in MLPA read ratios (no clear
baseline could be established). This could be because of the
DNA extraction procedure or presence of impurities (eg,
salt) in the extracted DNA. In three samples, no CNAs were
detected by digitalMLPA (G18, H03, and H05), which was
conﬁrmed for all three samples by aCGH and standard
MLPA (P335 ALL-IKZF1).
In the remaining 62 patient samples, a broad range of
CNAs were detected, ranging from whole chromosome
gains/losses, whole gene gains/deletions (both heterozygous
and homozygous), intragenic deletions (both heterozygous
and homozygous), and fusion genes to single-exon deletions
(Supplemental Table S4). As expected, different CNA
proﬁles were observed in the B- and T-ALL patient samples
included in this pilot study. For example, iAMP21 and copy
number changes of CD200/BTLA, IGHM, VPREB1, and
CASP8A2 were only observed in B-ALL patient samples,
whereas copy number changes of STIL-TAL1, LMO1,
LMO2, NF1, SUZ12, and PTPN2 were exclusively observed
in T-ALL patient samples. In addition, a larger number of
target genes showed CNAs in both T- and B-ALL patient
samples, such as CDKN2A/B, LEF1, MYB, MLLT3, and
PTEN, genes in the pseudoautosomal region 1, NR3C1, and
NR3C2.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Concordance between DigitalMLPA and Other Methods
Method
Ghent University
(Ghent, Belgium)
(n Z 35)
University of Helsinki
(Helsinki, Finland) (n Z 10)
Newcastle University
(Newcastle upon Tyne, UK)
(n Z 20)
DigitalMLPA version D007-X1-0316 D007-X1-0316 D007-X2-0816
Other method aCGH P335 aCGH SNPa P335 SNPa P335 P327
Total no. of CNAs 220 76 32 54 32 148 53 47
Counts conﬁrmed 216 73 12 25 30 145 47 47
Detected by other method but missed
by digitalMLPA (false negative)
1 3 1 12 0 0 1 0
Detected by digitalMLPA but missed by
other method (false positive)
3 0 19 17 2 3 5 0
Samples of Ghent University (nZ 35) and University of Helsinki (nZ 10) were tested using D007-X1-0316; samples of Newcastle University (nZ 20) were
tested using D007-X2-0816. Results of the digitalMLPA assay were compared with aCGH, SNPa, and/or standard MLPA assays P335 ALL-IKZF1 and P327 iAMP21-
ERG, when available. Total numbers of CNAs as observed by digitalMLPA, the number of counts conﬁrmed by each individual method, and the counts missed by
each method are included.
aCGH, array comparative genomic hybridization; CNA, copy number alteration; MLPA, multiplex ligation-dependent probe ampliﬁcation; SNPa, single-
nucleotide polymorphism array.
DigitalMLPA for T- and B-ALLAll detected CNAs were independently conﬁrmed by other
methods (aCGH and SNP arrays) and by data obtained with
standard MLPA assay P335 and/or P327, when applicable.
The concordance between digitalMLPA data and each of the
other methods is shown in Table 1. Overall diagnostic sensi-
tivity and speciﬁcity of the digitalMLPA assay (Table 2) were
calculated based solely on data obtained from the samples
from Ghent University (n Z 35) and Newcastle University
(15 of 20); as for the samples from the University of Helsinki
(n Z 10), many regions included in the digitalMLPA assay
were not covered on the SNP array and array CGH platforms.
For Newcastle University samples N15-N17 and N19-N20,
no array CGH or SNP array analyses were performed; these
samples (nZ 5) were also omitted from the calculations. As
we could not conclusively determine the number of false-
positive or false-negative calls for the above mentioned
samples (all 10 samples from the University of Helsinki andTable 2 Overall Diagnostic Sensitivity and Speciﬁcity of the
D007 DigitalMLPA Assay
Variable Value
Total counts* 544
Counts conﬁrmed by other method 481
Detected by other method but missed
by digitalMLPA (false negative)
5 Sensitivity: 0.99
Detected by digitalMLPA but missed by
other method (false positive)
11 Specificity: 0.98
The overall diagnostic sensitivity and speciﬁcity of the D007 digitalMLPA
assay have been calculated using the samples from Ghent University
(Ghent, Belgium) (n Z 35) and Newcastle University (Newcastle upon
Tyne, UK) (nZ 15; samples N15 to N17 and N19 to N20 were excluded as
no single-nucleotide polymorphism array or array comparative genomic
hybridization data were available for these samples). All counts have been
added up to calculate diagnostic sensitivity and speciﬁcity.
*Samples from Ghent University and Newcastle University.
MLPA, multiplex ligation-dependent probe ampliﬁcation.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgﬁve samples from Newcastle University), we excluded these
particular samples from the sensitivity and speciﬁcity calcu-
lations. As can be concluded from Tables 1 and 2, the D007
digitalMLPA assay performs well in comparison with other
methods and shows both high diagnostic sensitivity (98.9%)
and speciﬁcity (97.8%). False-positive or false-negative
ﬁndings detected in the samples used for the sensitivity and
speciﬁcity calculations, observed using digitalMLPA but not
using aCGH or SNP array (Supplemental Table S4) or vice
versa, were never reported for the same probes/regions in
multiple samples. False-positive CNAs detected by digital-
MLPA, but not conﬁrmed by aCGH or SNP array, included
VPREB1 deletion in sample G05, RAG2 exon 1 deletion in
sample N06, and PTEN exon 4 deletion in sample N07.
DigitalMLPA Identiﬁes Known and Novel Genetic
Aberrations in ALL
The digitalMLPA assay correctly detected the presence of
intrachromosomal fusion genes (via copy number change),
including STIL-TAL1 (heterozygous deletion of TAL1 exon
1 and STIL exons 2 to 12) (Figure 3A), NUP214-ABL1
(Figure 3B), and EBF1-PDGFRB (Figure 3C). The presence
of these fusion genes in the respective patient samples was
conﬁrmed by other methods. Of note, digitalMLPA will not
detect inversions, balanced translocations, or copy number
changes that lie outside (or only partially inside) the
sequence detected by an MLPA probe.
Somatic loss of the entire Y chromosome was detected in
one ALL sample, which was conﬁrmed by cytogenetic
analysis. One case harbored a heterozygous deletion of
CD200 and a homozygous deletion of BTLA. In addition to
whole gene deletions, multiple intragenic deletions (both
heterozygous and homozygous) were observed in different
patient samples, including PAX5 (exons 2 to 6), IKZF1
(exons 1 to 3, 1 to 7, and 4 to 7), RUNX1 (exons 2 to 4, 4 to665
Figure 3 Intrachromosomal fusion genes identiﬁed in ALL patient
samples. DigitalMLPA detects several intrachromosomal fusion genes,
including STIL-TAL1 fusion and heterozygous deletion of TAL1 exon 1
and STIL exons 2 to 12 (A), NUP214-ABL1 fusion and gain of one copy
of ABL1 exons 3 to 11 and NUP214 exons 2 to 23 (an additional probe
for NUP214 exon 29 has been added in D007-X2-0816) (B), and EBF1-
PDGRFB fusion and deletion of EBF1 exon 16 and PDGFRB exons 9 to 10
(C). The y axis represents read ratio as compared with the reference
samples.
Benard-Slagter et al6, and 8 to 9), RB1 (exons 19 to 26), CDKN2A (exon 1 plus
upstream probes, exons 2 to 4, and exons 2 to 5), PHF6
(exons 1 to 3), LEF1 (exons 3 to 4 and 4 to 12), PTEN
(exons 1 to 5, 2 to 3, and 2 to 5), MLLT3 (exons 2 to 5),
ETV6 (exons 1 to 2, 2 to 5, and 6 to 8), and ERG (exons 5 to
12 and 5 to 9) (Figure 4A). Although most samples with
NR3C1 CNAs showed heterozygous deletions, one case
harbored a gain of NR3C1 exons 5 to 8 and a simultaneous
heterozygous deletion of exons 1 and 2 (Figure 4B). Most
deletions of VPREB1 were heterozygous deletions of the
whole gene, but in four cases, a heterozygous deletion was
observed at the start of exon 2; the probe at the end of exon
2 showed a homozygous deletion. We also identiﬁed several
cases with single-exon deletions, including heterozygous
deletions of BTG1 exon 2 (plus downstream probes),
MLLT3 exon 1, 2, or 7, RUNX1 exon 4, NR3C2 exon 2,
FHIT exon 4, P2RY8 exon 2, RAG2 exon 1, PTEN exon 4,
ETV6 exon 1 or 2, homozygous deletion of IKZF1 exon 8
(Figure 4C), both heterozygous and homozygous deletion of
LEF1 exon 3 (Figure 4D) and MLLT3 exon 2. All intragenic
deletions, including most reported single-exon deletions,
were conﬁrmed by aCGH and/or SNP arrays.
In addition to gene/exon deletions, gains were also
detected. Among the patient samples tested, we identiﬁed
one case displaying high hyperdiploidy (Figure 5A), which
was correctly identiﬁed by digitalMLPA; by aCGH analysis,
this case was misinterpreted as bearing multiple chromo-
somal losses. In two patient samples, a gain of MYB was666observed. Intragenic gains of ETV6 exons 1 to 5 or 2 to 5
and RUNX1 exons 4 to 9 (and downstream 21q probes) were
also observed, as well as single-exon gains, such as P2RY8
exon 1 and PTEN exon 5. iAMP21, currently deﬁned as
more than four copies of RUNX1 on a single abnormal
chromosome 21, as detected by FISH, was identiﬁed in 11
cases (Figure 5B), whereas gain of entire chromosome 21
was observed in six cases (Figure 5C).
Detection of Subclonal Copy Number Changes
Subclonal copy number changes were simulated using
DNA from three B-ALL patient samples diluted to 50%,
30%, 25%, 20%, 15%, and 10% with corresponding
remission material of the same patient. Using a cutoff value
of 0.12 (as described in Materials and Methods), subclonal
CNAs were reliably detected by the digitalMLPA assay if
present in at least 20% to 30% of neoplastic cells (Table 3).
One of the samples was obtained from a Down syndro-
meeassociated ALL patient, explaining the gain of chro-
mosome 21 with a read ratio of approximately 1.5 in all
dilutions.
DigitalMLPA Using Minimal Amounts of Input DNA
Results from the experiments using low amounts of input
DNA showed that digitalMLPA performs robustly on low
amounts of DNA (some examples are included injmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 4 Intragenic and single-exon deletions identiﬁed in ALL patient samples. Several intragenic deletions are successfully identiﬁed in ALL patient
samples, including deletion of ERG exons 5 to 9 (A), deletion of NR3C1 exons 1 and 2 and upstream region on a background of gain of one allele of NR3C1
exons 5 to 8 (B), homozygous deletion of IKZF1 exon 8 (two probes are included for each exon of IKZF1) (C), and homozygous deletion of LEF1 exon 3 (D). All
copy number changes were conﬁrmed by other methods. The y axis represents read ratio as compared with the reference samples.
DigitalMLPA for T- and B-ALLTable 4). Read ratios for copy number gains and hetero-
zygous and homozygous losses are stable, even when
using only 5 ng of input DNA. Of note, when using <20
ng of input DNA, the number of unidentiﬁed reads (whichFigure 5 Gain of whole chromosomes or chromosomal regions in ALL patien
digitalMLPA. A: A case of high hyperdiploidy correctly identiﬁed by digitalMLPA
ampliﬁcation of chromosome 21 (iAMP21) showing the typical copy number proﬁl
changes were conﬁrmed by other methods. The y axis represents read ratio as co
The Journal of Molecular Diagnostics - jmd.amjpathol.orginclude incomplete probes and wrong combinations of
right- and left-hybridizing sequences) increases markedly.
Therefore, the use of 20 ng of input DNA for this dig-
italMLPA assay is recommended.t samples. Gain of whole genes or chromosomal regions as identiﬁed by
showing the characteristic whole chromosome gains. B: Intrachromosomal
e along chromosome 21. C: Gain of entire chromosome 21. All copy number
mpared with the reference samples.
667
Table 3 Read Ratios of the Dilution Series
Sample Gene/region Aberration
Dilution (%)
100 50 30 25 20 15 10
G11 Chromosome 4 Gain 1.37 1.16 1.09 1.07 1.03 1.02 1.02
Chromosome 6 Gain 1.36 1.12 1.09 1.03 1.00 1.03 1.02
Chromosome 14 Gain 1.39 1.16 1.13 1.09 1.05 1.11 1.05
Chromosome 17 Gain 1.36 1.16 1.13 1.08 1.08 1.07 1.06
Chromosome 18 Gain 1.37 1.18 1.09 1.06 1.05 1.07 1.04
Chromosome 21 Gain 1.80 1.36 1.21 1.17 1.14 1.10 1.08
Chromosome X Gain 1.86 1.38 1.24 1.16 1.14 1.16 1.08
Pseudoautosomal region 1 Gain 1.36 1.17 1.12 1.06 1.05 1.06 1.06
G09 CD200 Deletion 0.55 0.75 0.86 0.89 0.89 0.88 0.89
BTLA Deletion 0.50 0.73 0.83 0.83 0.92 0.91 0.94
IKZF1 exons 1-7 Deletion 0.54 0.75 0.87 0.87 0.90 0.91 0.99
8q Arm including TOX Gain 1.45 1.22 1.13 1.12 1.08 1.05 1.05
MTAP Deletion 0.08 0.51 0.61 0.64 0.71 0.81 0.83
CDKN2A exons 2-4 Deletion 0.09 0.50 0.63 0.67 0.72 0.77 0.85
CDKN2A exon 1 þ up Deletion 0.51 0.70 0.80 0.77 0.91 0.84 0.93
CDKN2B exon 2 Deletion 0.52 0.76 0.78 0.77 0.87 0.86 0.87
20q13 Deletion 0.52 0.77 0.88 0.87 0.88 0.86 0.95
G01 CD200 Deletion 0.48 0.79 0.88 0.95 0.91 0.99 1.01
BTLA Deletion 0.00 0.63 0.75 0.82 0.83 0.92 0.98
6q22.33-q27 including MYB Gain 1.44 1.16 1.12 1.08 1.11 1.06 1.04
9p22.2-p24.3 Deletion 0.51 0.74 0.85 0.86 0.88 0.92 0.94
MTAP Deletion 0.50 0.73 0.77 0.91 0.87 0.95 0.98
CDKN2A Deletion 0.02 0.59 0.77 0.78 0.83 0.87 0.87
CDKN2B exon 2 Deletion 0.00 0.56 0.73 0.77 0.82 0.87 0.89
PAX5 Deletion 0.50 0.82 0.88 0.92 0.95 0.98 1.01
RB1 Deletion 0.49 0.78 0.94 0.93 0.95 0.97 0.97
IGHM Deletion 0.59 0.79 0.87 0.93 0.91 0.97 0.92
Chromosome 21 Gain 1.47 1.48 1.51 1.5 1.49 1.52 1.49
VPREB1 Deletion 0.48 0.77 0.86 0.86 0.95 0.93 0.90
Average read ratios across the gene or region of the dilution series of three lymphoblastic leukemia patient samples diluted with remission material of the
same patient are listed. Dilutions tested were 50%, 30%, 25%, 20%, 15%, and 10% and matched to the correct patient sample using the undiluted patient
sample (100%). Boldface are values <0.88 as these would be classiﬁed as a deletion, or >1.12 as these would be classiﬁed as a gain.
Benard-Slagter et alDiscussion
The advent of high-resolution, microarray-based techniques,
such as aCGH, has enabled the identiﬁcation of multiple
novel, often submicroscopic, DNA copy number alterations
targeting key cellular pathways in ALL, several of which are
clinically relevant and can be integrated into the risk clas-
siﬁcation of ALL patients.4 In diagnostic laboratories,
conventional karyotyping is used to identify gross ploidy
changes and FISH is used for detection of translocations.
However, with these techniques, some submicroscopic
CNAs may be missed. For example, the most common
deletion of IKZF1 (deletion 4 to 7, approximately 50 kb) is
not detectable by bacterial artiﬁcial chromosome FISH
because of the probe size limitation. Deletion of CDKN2A is
underestimated by bacterial artiﬁcial chromosome FISH in
15% of ALL patients for the same reason.15 Next-generation
sequencing methods are available to detect point mutations,
fusion genes, and copy number changes, but these are labor
intensive and costly. This digitalMLPA assay was668developed not aiming at replacing these techniques, but
rather to accommodate an unmet need for accurate copy
number detection of multiple genomic regions involved in
ALL (eg, IKZF1 and ERG) in a single experiment.
Our study demonstrates that digitalMLPA is a robust and
reliable technique that can be used to genetically charac-
terize ALL patients. The expected copy number changes
were observed in all positive control cell lines, and most
CNAs observed in patient samples were independently
conﬁrmed by other methods, including aCGH, SNP arrays,
and standard MLPA assays.
Most CNAs observed in ALL patient samples were well-
known, including intrachromosomal fusion genes, whole
gene and intragenic deletions/gains, whole chromosome
gains, and CNAs typically observed in either B- or T-ALL
subtypes. Interestingly, we identiﬁed a sample harboring a
heterozygous deletion of CD200 and a homozygous dele-
tion of BTLA, which has been previously described,9
although heterozygous deletion of both genes is more
common. Various previously described intragenic deletionsjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 4 DigitalMLPA Using Low Amounts of Input DNA
Region
Research cell line sample 1 Research ALL sample 2 Research ALL sample 3
40 ng 30 ng 20 ng 15 ng 10 ng 5 ng 40 ng 30 ng 20 ng 15 ng 10 ng 5 ng 40 ng 30 ng 20 ng 15 ng 10 ng 5 ng
RB1
Exon 5 1.51 1.49 1.56 1.57 1.59 1.50 0.98 0.99 0.92 0.94 0.99 1.05 1.03 1.02 0.99 1.09 1.09 1.06
Exon 14 1.45 1.46 1.44 1.50 1.45 1.55 0.92 0.92 0.95 1.11 1.01 1.15 1.04 1.04 1.05 0.98 1.05 0.93
Exon 19 1.54 1.43 1.53 1.34 1.53 1.54 0.00 0.00 0.00 0.00 0.00 0.00 1.15 1.16 1.06 1.00 1.11 1.07
Exon 24 1.50 1.53 1.56 1.51 1.44 1.47 0.00 0.00 0.00 0.00 0.00 0.00 1.11 1.10 1.06 1.02 1.07 1.06
Exon 26 1.51 1.48 1.47 1.48 1.41 1.60 0.00 0.00 0.00 0.00 0.00 0.00 1.01 1.10 1.07 1.12 1.03 1.08
CD200
Exon 3 1.02 1.02 1.02 1.03 1.07 1.14 0.53 0.52 0.53 0.52 0.48 0.51 1.06 1.12 1.10 1.04 1.09 1.10
Exon 4 0.97 0.96 0.99 0.96 1.02 1.00 0.49 0.46 0.45 0.52 0.45 0.50 1.04 0.93 0.97 0.97 1.00 1.05
Exon 6 1.07 1.00 0.95 1.01 1.03 0.95 0.50 0.46 0.49 0.47 0.47 0.57 1.03 0.97 1.00 1.07 1.14 0.98
BTLA
Exon 5 1.02 0.96 1.00 0.99 0.94 0.98 0.48 0.48 0.47 0.44 0.50 0.49 1.03 0.97 1.01 0.95 1.01 0.94
Exon 2 0.98 0.93 1.09 1.00 1.07 0.87 0.45 0.47 0.47 0.47 0.53 0.55 1.00 1.00 1.04 0.89 0.92 0.93
Exon 1 1.00 0.99 1.11 1.17 1.03 0.94 0.50 0.48 0.48 0.48 0.47 0.59 0.97 1.06 0.97 0.97 1.08 0.95
ETV6
Exon 1 0.96 1.05 0.92 1.00 1.00 0.95 0.00 0.00 0.00 0.00 0.00 0.00 1.01 0.99 1.05 1.01 1.03 0.84
Exon 2 1.00 0.95 0.93 1.04 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 1.10 1.11 1.10 0.97 1.08 1.07
Exon 3 1.06 1.03 1.00 0.98 0.94 1.02 0.00 0.00 0.00 0.00 0.00 0.00 1.04 1.06 1.07 1.02 0.95 1.01
Exon 4 1.00 1.03 0.95 0.97 0.90 1.00 0.50 0.51 0.51 0.50 0.50 0.45 1.07 1.22 1.08 1.08 1.19 1.11
Exon 5 1.02 0.95 1.02 1.05 1.00 0.89 1.04 1.00 0.99 0.97 1.00 0.93 1.13 1.02 1.09 1.07 1.01 1.11
Exon 6 1.02 1.01 1.02 1.02 0.97 1.11 0.94 1.01 0.96 0.89 0.95 0.82 1.08 1.05 1.04 0.96 1.05 1.15
Exon 7 0.94 1.08 0.96 0.97 1.03 1.03 0.93 0.96 0.91 0.95 0.96 0.87 1.03 1.02 1.10 1.01 0.95 1.10
Exon 8 1.07 1.00 1.03 1.01 0.89 0.95 0.97 0.98 1.00 0.92 1.03 1.01 1.06 1.04 1.07 1.04 1.02 1.07
IKZF1
Exon 1, probe 1 0.93 0.90 0.85 0.87 0.95 0.90 0.92 0.92 0.90 0.94 0.87 0.86 1.06 1.07 1.05 0.91 1.06 1.06
Exon 1, probe 2 0.85 0.88 0.86 0.90 0.84 0.99 0.96 0.91 0.85 0.93 0.89 0.99 0.64 0.65 0.62 0.66 0.68 0.68
Exon 2, probe 1 0.89 0.84 0.92 0.89 0.98 0.88 0.88 0.95 0.88 0.87 0.98 0.93 0.65 0.67 0.68 0.68 0.64 0.65
Exon 2, probe 2 0.84 0.91 0.88 0.88 0.85 0.96 0.97 0.89 0.82 0.90 0.84 1.02 0.67 0.66 0.68 0.62 0.76 0.68
Exon 3, probe 1 0.93 0.97 0.91 0.92 0.94 1.01 0.95 0.92 0.89 0.89 0.93 0.82 0.66 0.72 0.68 0.63 0.67 0.70
Exon 3, probe 2 0.93 0.97 0.88 0.94 0.97 0.94 0.98 0.95 0.91 0.90 0.87 0.79 0.71 0.75 0.77 0.66 0.63 0.77
Exon 4, probe 1 0.90 0.93 0.90 0.88 0.99 0.94 0.46 0.44 0.46 0.48 0.41 0.40 0.29 0.31 0.29 0.34 0.34 0.30
Exon 4, probe 2 0.91 0.90 0.87 0.86 0.94 0.91 0.41 0.45 0.48 0.44 0.41 0.43 0.26 0.30 0.29 0.25 0.31 0.28
Exon 5, probe 1 0.91 0.89 0.99 0.94 0.97 0.91 0.43 0.45 0.45 0.38 0.43 0.52 0.30 0.31 0.33 0.29 0.31 0.25
Exon 5, probe 2 0.90 0.87 0.98 0.92 0.99 0.86 0.46 0.44 0.47 0.50 0.43 0.45 0.33 0.32 0.32 0.30 0.32 0.27
Exon 6, probe 1 0.91 0.91 0.93 0.83 0.96 0.86 0.44 0.49 0.48 0.39 0.43 0.48 0.32 0.32 0.31 0.24 0.26 0.21
Exon 6, probe 2 0.90 0.89 0.87 0.90 0.89 0.98 0.45 0.47 0.45 0.44 0.45 0.41 0.30 0.28 0.30 0.30 0.30 0.31
Exon 7, probe 1 0.89 0.94 0.97 0.89 0.91 0.87 0.49 0.46 0.49 0.45 0.48 0.38 0.29 0.31 0.32 0.23 0.27 0.26
Exon 7, probe 2 0.96 0.93 0.93 0.94 0.92 0.82 0.45 0.45 0.48 0.45 0.46 0.42 0.29 0.32 0.32 0.26 0.29 0.26
Exon 8, probe 1 0.88 0.94 0.87 1.00 0.89 0.86 0.86 1.00 0.88 0.87 0.88 0.91 1.02 0.98 1.02 1.02 0.94 1.13
Exon 8, probe 2 0.90 0.86 0.86 0.86 0.88 0.80 0.89 0.90 0.91 0.86 0.93 0.86 0.97 1.05 1.04 0.88 1.04 1.03
Unidentiﬁed reads 0.99 1.03 1.09 1.16 1.29 1.67 0.98 1.11 1.23 1.23 1.30 1.95 1.09 1.21 1.16 1.46 1.76 1.94
Displayed are read ratios from digitalMLPA experiments using varying amounts of input DNA. The dilution series tested included 40 (standard), 30, 20, 15,
10, and 5 ng of input DNA. Copy number gains are boldfaced, heterozygous losses are underlined italic, and homozygous losses are boldfaced italic. Un-
identiﬁed reads include incomplete probes and wrong combinations of right- and left-hybridizing sequences.
ALL, lymphoblastic leukemia; MLPA, multiplex ligation-dependent probe ampliﬁcation.
DigitalMLPA for T- and B-ALLwere detected using digitalMLPA, including PAX5 exons
2 to 6,16 IKZF1 exons 4 to 7,17e19 RB1 exons 19 to 26,19
ETV6 exons 6 to 8,20,21 and BTG1, harboring a breakpoint
in exon 2.22 In addition to these well-known CNAs, several
interesting intragenic deletions were observed, including an
intragenic deletion of ERG exons 5 to 9. Previously
described intragenic deletions of ERG encompass mostly
deletions of exons 3 to 7, exons 3 to 8, or exons 3 to 9.23,24
We found no evidence in the literature describing intra-
genic deletions of ERG exons 5 to 9, as observed in one ofThe Journal of Molecular Diagnostics - jmd.amjpathol.orgour patient samples. The clinical signiﬁcance of this spe-
ciﬁc intragenic deletion is therefore unknown, but it would
be expected to be equivalent to other intragenic deletions of
ERG. Similarly, rare intragenic deletions of PTEN exons 1
to 5, exons 2 to 3, or exons 2 to 5 were observed. There are
only a few previous reports of intragenic PTEN deletions
(eg, exons 2 to 3 or exons 4 to 5).25 There are no previous
reports describing intragenic deletions of RUNX1 exons 2
to 4 or CDKN2A exons 2 to 5, as were observed in our set
of patient samples using digitalMLPA.669
Benard-Slagter et alSeveral rare single-exon deletions were also detected,
including a homozygous deletion of IKZF1 exon 8. IKZF1
exon 8 encodes two zinc ﬁngers, which are required for
homodimerization of IKZF1 or heterodimerization with
other transcription factors.26 Deletions of IKZF1 exon 8 are
rare, but have been described in several studies and seem to
be associated with a poor outcome.27,28 Another interesting
case showed a homozygous deletion of LEF1 exon 3,
whereas the other exons of LEF1 showed a heterozygous
deletion. Deletions with distinct regions of heterozygous
and homozygous deletions, suggesting that the two LEF1
alleles were affected by independent genetic events, have
been described previously.29 Intragenic deletions of
VPREB1 have also been described in the literature, although
most articles have not speciﬁed the exact breakpoints.30
VPREB1 deletions have been reported to be associated
with decreased survival.31 Finally, we identiﬁed several
novel single-exon deletions in LEF1, FHIT, and ETV6,
gains of ETV6 exons 1 to 5, or single-exon gains, such as
P2RY8 exon 1 or PTEN exon 5. It will be interesting to
study the prevalence and clinical impact of these single-
exon deletions in larger patient cohorts.
Another interesting result was one of high hyperdiploidy,
which was misinterpreted as bearing multiple chromosomal
losses on the basis of aCGH data. However, on the basis of
the DNA index, it was concluded that this case should be
regarded as high hyperdiploid in contrast to the hypodiploid
state called by aCGH. As the absolute read numbers per
sample are compared with a set of reference samples with
normal copy number for all sequences included in this
digitalMLPA assay, we were able to correctly identify a
gain of 14 chromosomes in this high-hyperdiploid ALL
patient sample. This case would likely have been identiﬁed
correctly using conventional karyotyping or multilocus
FISH. However, in cases with failed cytogenetics because of
low numbers of dividing cells and concurrent problems with
banding techniques, digital karyotyping with multiple
probes covering all chromosome arms, as in this digital-
MLPA assay, offers a reliable solution.
Both diagnostic sensitivity (98.9%) and speciﬁcity
(97.8%) were high, as determined by comparing the digi-
talMLPA data to previously obtained aCGH data (Ghent
University and Newcastle University). Aberrations not
conﬁrmed by aCGH and/or SNP array were mostly single-
exon deletions (samples G02, N06, and N07) or subclonal
deletions with relative read ratios >0.76 (samples G07 and
N05). Several other subclonal alterations, however, were
conﬁrmed by aCGH and/or SNP array (samples G10 and
N11). The false-positive results from digitalMLPA
(VPREB1, RAG2 exon 1, and PTEN exon 4), which were
not conﬁrmed by other methods, are unlikely to inﬂuence
risk stratiﬁcation. Single-exon deletions detected by digi-
talMLPA should always be conﬁrmed by other methods.
To determine the detection limit for subclonal CNAs, we
performed the ALL digitalMLPA assay on three B-ALL
patient samples diluted with remission material from the670same patient. Results from this dilution series indicated that
subclonal alterations could be reliably detected with this
digitalMLPA assay if present in at least 20% to 30% of
neoplastic cells, which is comparable to the detection limits
observed with standard MLPA.7,32,33 Detection limits for
subclonal alterations are dependent on the type of CNA
present in the DNA sample. Homozygous deletions and high-
level ampliﬁcations were easier to detect, even in highly
diluted samples (down to 10% of neoplastic cells), whereas
heterozygous deletions and one copy gains could be detected
down to 25% to 30% of neoplastic cells. Inclusion of a higher
number of digitalMLPA probes per target gene/region could
possibly further lower the detection limit as statistically,
subtle changes in read ratios of multiple adjacent probes
could be more easily detected to make the call for a subclonal
deletion. As the percentage of ALL blasts used for DNA
analysis is usually >70%, any CNA in the major clone will
be accurately detected using digitalMLPA.
Advantages of digitalMLPA, as compared with other
genetic methods, include a high dynamic range for copy
number detection, a robust assay concerning impurities in
the DNA sample as compared with standard MLPA, and the
requirement of only small amounts (20 ng) of DNA.
Usually, the amount of material available for DNA extrac-
tion in ALL patients is not an issue at diagnosis. However,
use of small amounts of DNA allows laboratories to spare
sufﬁcient material for yet to be deﬁned research experiments
while maintaining appropriate clinical care. Alternatively,
only low amounts of DNA may be available from valuable
ALL patientederived archived material (eg, from rare
specimens within a research setting). With digitalMLPA, a
large number of genomic loci of interest can be analyzed for
copy number alterations in a single reaction with low hands-
on time, and results are available within 36 hours. Because
of the targeted approach, data analysis and result interpre-
tation will be much easier as compared with array CGH or
genome-wide sequencing platforms. DigitalMLPA can also
be used for analysis of complex regions, such as the PTEN
gene. In addition, as speciﬁc barcodes are used in the MLPA
reactions, the PCR-ampliﬁed samples can be combined with
any other sequencing reaction in one Illumina run. During
data analysis, the MLPA reactions can also easily be sepa-
rated from other sequencing data.
In conclusion, we have shown that digitalMLPA is a
reliable technique to detect key CNAs in ALL. The digi-
talMLPA ALL probe mix is to be tested in independent
laboratories and on a larger scale to assess its clinical and
diagnostic utility. The results presented merit further
consideration of digitalMLPA as a valuable alternative for
genetic testing of newly diagnosed ALL patients.Acknowledgments
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